Stock Taper
InflaRx N.V., a German and U.S.-based biopharma, develops C5a inhibitors like vilobelimab for autoimmune and inflammatory diseases, with multiple products in clinical trials.

Gohibic, a first-in-class monoclonal antibody by InflaRx, inhibits C5a to reduce inflammation and is authorized in the EU and EUA in the U.S. for treating critically ill COVID-19 ARDS patients.
| Map | REGION | FY2022 |
|---|---|---|
![]() | GERMANY | $4.9M |
![]() | UNITED STATES | $100K |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
STTK | $7.04 | COMPARE |
ARTV | $11.09 | COMPARE |
STRO | $20.45 | COMPARE |
CNTB | $2.23 | COMPARE |
KLRS | $4.03 | COMPARE |
IMA | $5.34 | COMPARE |
ATYR | $0.54 | COMPARE |
MGX | $1.19 | COMPARE |